AL Amyloidosis: Unfolding a Complex Disease
Rebecca Lu, MS, FNP, and Tiffany A. Richards, PhD, ANP-BC
The University of Texas MD Anderson Cancer Center, Houston, Texas
Authors’ disclosures of conflicts of interest are found at the end of this article.
Rebecca Lu, MS, FNP,
1515 Holcombe Boulevard, Houston, TX 77030
J Adv Pract Oncol 2019;10(8):813–825 |
© 2019 Harborside™
Light chain (AL) amyloidosis is a rare plasma cell dyscrasia. An estimated 12,000 people live with the disease in the United States. AL amyloidosis occurs from the misfolding of proteins that deposit in organs (heart, kidneys, digestive tract, tongue, lungs, and nervous system), leading to progressive organ damage and impairment of quality of life. The treatment of AL amyloidosis has improved greatly over the past several years, with new treatments currently in development. This article will focus on the pathophysiology, diagnosis, and treatment of AL amyloidosis.
For access to the full length article, please sign in